CBC’s The National interviewed Michael Hayden, a professor in the department of medical genetics at UBC, about Glybera, the world’s first drug approved to treat a genetic disease which he helped develop, but which is now unavailable due to costs.
“To be quite frank, this was not something I was particularly proud of — that the pricing of this made it out of the reach. The whole motivation for doing this was to have this available for patients,” said Hayden